major histocompatibility complex, class II, DR beta 6 (pseudogene)Genealiases: []
Q-omics provides the consensus-scored HLA-DRB6 profile across patient tissues and cancer cell-line models. HLA-DRB6 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, HLA-DRB6 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, HLA-DRB6 RNA expression shows 13,172 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight SKCM, KIRC, and SARC as cancer lineages where HLA-DRB6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HLA-DRB6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HLA-DRB6 survival associations across molecular data types. HLA-DRB6 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HLA-DRB6 RNA expression–survival associations across cancer types. High HLA-DRB6 expression shows unfavorable associations in UVM, LGG and LAML, but favorable associations in SKCM, HNSC and LIHC. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for HLA-DRB6 RNA expression.
This table summarizes HLA-DRB6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for HLA-DRB6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HLA-DRB6 shows lower tumor expression in LUAD, LUSC and KICH and higher tumor expression in KIRC, THCA and ESCA. The KIRC box plot shows higher HLA-DRB6 RNA expression in tumor versus normal tissue (log2 FC = +1.924, t-test p < 0.001).
This table shows molecular features associated with HLA-DRB6 in patient tissues and cancer cell lines. In patient samples, HLA-DRB6 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set. In cancer cell lines, HLA-DRB6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in STOMACH.
